| 摘要 |
Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPARdelta with sulfonyl-substituted bicyclic compounds and compositions as pharmaceuticals.
|
